UT Southwestern researchers identify brain pathway linked to clozapine weight gain

Researchers at UT Southwestern Medical Center have uncovered a specific brain signaling pathway that appears to drive the significant weight gain frequently seen in patients taking clozapine, a commonly prescribed antipsychotic for treatment‑resistant schizophrenia. The pre‑clinical study, reported in *Nature Communications*, demonstrates that disrupting this pathway in animal models reduces the drug’s metabolic side effects without compromising its antipsychotic efficacy.

The investigation focused on neural circuits that regulate energy balance and appetite. By targeting key molecules within this pathway, the researchers were able to blunt the weight‑promoting effects of clozapine while preserving its therapeutic benefits. The findings suggest a promising avenue for developing adjunct therapies that could mitigate clozapine’s well‑known metabolic risks, potentially improving long‑term health outcomes for patients who rely on this medication.

If translated to humans, the study could lead to new treatment strategies that allow clinicians to use clozapine’s powerful antipsychotic action while minimizing the risk of obesity and related metabolic disorders, thereby enhancing both safety and quality of life for individuals with treatment‑resistant schizophrenia.